Full-Time

IT Manager

Treasury Apps, Plt & Reliability

Posted on 9/27/2025

Johnson & Johnson

Johnson & Johnson

10,001+ employees

Global healthcare company offering pharma, devices.

Compensation Overview

$100k - $172.5k/yr

+ Annual performance bonus + Company sponsored employee benefit programs + pension and 401(k) + time off benefits

Bridgewater Township, NJ, USA

In Person

Category
IT & Security (3)
, ,
Required Skills
SAP Products
Risk Management
iOS/Swift
Requirements
  • Bachelor's degree in Information Systems or Computer Science, or relevant work experience.
  • 7+ years of overall experience in SAP Global Finance applications and technology components
  • 5+ years of experience as SAP Treasury consultant having experience in Bank & Cash management, Transaction manager, In-house Banking (IHB), Risk analyzers, Liquidity planner, Hedge management and accounting, SWIFT integration, Bank Communication Management (BCM), integration with financial accounting and other applications.
  • Have strong systematic problem-solving experience, a sense of accountability, ownership and drive.
  • Expertise in ITIL processes (incident management, change, problem, release management)
  • Expertise in collaboratively managing diverse relationships across geography and culture
  • Focus on business outcomes, strategic thinker with ability to prioritize team goals and activities
  • Strong communication verbal & written; creating sound arguments, or to adequately representing both business and IT implications during a Major Service Disruption
  • Demonstrated ability to work independently and manage multiple projects simultaneously in a fast- paced environment
  • Strong leadership qualities including being enthusiastic, thoughtful, thorough, decisive, and flexible, conducting yourself professionally and with integrity.
  • Make confident decisions and drive results through others while fostering collaboration and innovation
  • Employ best practices for talent management, assessment and diversity and inclusion
  • Seek out and apply feedback toward your own performance and career goals
  • 10% travel- domestic/international
  • SAP Treasury Certification is preferable
Responsibilities
  • SAP S4 HANA Treasury Support
  • SAP S/4 Treasury Configuration & Maintenance: Proven experience in configuring, building, and maintaining the SAP S/4 Treasury module, aligning with J&J business requirements for cash management, payment factory, financial risk management, and other treasury functions.
  • System Integration Management: Oversee and manage system integrations between SAP S/4 modules, reporting systems, and third-party applications to ensure seamless data flow, process efficiency, and data accuracy.
  • Technical Support & Issue Resolution: Provide expert technical support by diagnosing and resolving issues related to the SAP Treasury system. Collaborate with IT teams to address system defects, bugs, and outages promptly.
  • Support Cutover & Deployment Activities: Coordinate support activities during system maintenance, upgrades, or the implementation of new functionalities to ensure uninterrupted treasury operations.
  • Treasury Process Guidance: Offer strategic guidance on treasury management processes, including Hedge Management Cockpit, cash flow forecasting, cash positioning, risk management, and investment management, leveraging SAP FSCM capabilities.
  • Service Level Management
  • Manage SLA & service delivery against SLAs and key performance indicators (KPIs) to ensure compliance
  • Engage with multiple stakeholders such as Technology Product Owners (TPO) and Business Leads to regularly report on service performance, highlighting accomplishments, issues, and areas for improvement
  • Event, Incident & Problem Management
  • Oversee the incident management process, ensuring correct prioritization and swift response to minimize service disruptions. Monitor and analyze incident trends and metrics to provide insights for performance improvement
  • Lead investigations into major incidents to identify root causes. Managing & providing guidance in analyzing problems for identifying the root cause. Collaborate with relevant teams to implement corrective and preventive actions, ensuring that issues are resolved effectively and do not recur.
  • Service Request Management
  • Oversee the overall process to ensure that requests are accurately documented and assigned to the appropriate teams for resolution, facilitating efficient handling and tracking.
  • Continuously evaluate and refine the service request management process to enhance efficiency and user satisfaction. Analyze trends in service requests to identify common issues and opportunities for process adjustments, training, or knowledge base updates
  • Knowledge Management
  • Responsible for managing transition from Project teams and ensuring support readiness
  • Responsible for ensuring that knowledge is used appropriately across Inc and SRM
  • Continuous Service Improvement
  • Monitor and measure the quality of IT operations, benchmark metrics, perform analysis and identify service improvement opportunities, self-service capabilities & automation to improve the overall service delivery (e.g. ticket trends that should initiate chronic problem process, ticket reassignments).
  • Stay updated with the latest SAP Treasury features and enhancements. Evaluate and recommend new tools or processes to improve treasury operations and drive efficiency
Desired Qualifications
  • SAP Treasury Certification is preferable

Johnson & Johnson operates in three main areas—pharmaceuticals, medical devices, and consumer health products—serving consumers, healthcare professionals, and institutions worldwide. It develops prescription medicines, sells surgical and vision care devices, and offers over-the-counter and personal care products, funded by direct sales, partnerships, and distribution agreements, with heavy investment in research and development. The company differentiates itself by combining three complementary businesses under one umbrella and maintaining a global footprint with an emphasis on science, innovation, and inclusive culture. Its goal is to help people live healthier lives by delivering reliable, high-quality healthcare products and solutions that improve patient outcomes.

Company Size

10,001+

Company Stage

IPO

Headquarters

New Brunswick, New Jersey

Founded

1886

Simplify Jobs

Simplify's Take

What believers are saying

  • Q1 2026 revenue hit $24.1 billion, up 9.9%, raising 2026 forecast to $100.8 billion.
  • Nipocalimab gains FDA Priority Review for autoimmune hemolytic anemia and myasthenia gravis efficacy.
  • Shockwave C2 Aero launches in US and Japan targeting 315 million calcified CAD patients.

What critics are saying

  • Stelara sales plunge 60% to $656 million in Q1 2026 post-patent expiration, creating $2.3 billion hole.
  • Icotyde stalls at 1,500 prescriptions, missing oncology targets by Q3 2026.
  • CAPLYTA faces Invega Sustenna competition, achieving under 10% adoption by mid-2027.

What makes Johnson & Johnson unique

  • J&J unites Innovative Medicine and MedTech under single brand since September 2023.
  • DARZALEX and TREMFYA dominate oncology and immunology with $57 billion pharma sales in 2024.
  • CARTO System leads electrophysiology for 30 years with AI-powered CARTOSOUND SONATA.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Paid Sick Leave

Paid Holidays

Remote Work Options

Performance Bonus

Company News

Yahoo Finance
Apr 14th, 2026
J&J's Spravato hits $468M in Q1 sales, signalling upside for psychedelics peers like Atai

Johnson & Johnson's Spravato reported $468 million in first-quarter 2026 sales, up 46% year over year, signalling potential for psychedelics-focused companies like AtaiBeckley Inc., according to Jefferies analysts. The esketamine nasal spray, approved for treatment-resistant depression, is on track to reach an annualised run rate exceeding $1.9 billion. Jefferies maintained that Spravato could hit $3 billion in annual sales by 2027 and $5 billion at peak. Over 200,000 patients have been treated globally, up from 140,000 at the start of 2025. Analysts said Spravato's commercial success demonstrates psychedelics can succeed in mainstream healthcare, with existing treatment infrastructure potentially easing adoption of emerging therapies. They highlighted ATAI's intranasal candidate BPL-003 as fitting seamlessly into Spravato's treatment paradigm.

Yahoo Finance
Apr 14th, 2026
J&J hits $100B milestone with 6.4% growth, eyes double-digit revenue by decade's end

Johnson & Johnson reported 6.4% operational sales growth in Q1 2026, raising full-year guidance to $100.2 billion — the first time the company has reached the $100 billion milestone. The company reaffirmed expectations for double-digit revenue growth by decade's end. Innovative Medicine grew 7.4%, driven by 10 double-digit growing brands including DARZALEX and TREMFYA, despite a 61.7% decline in STELARA due to biosimilar competition. MedTech posted 4.6% growth, led by heart recovery and electrophysiology divisions. The company successfully launched ICOTYDE, the first oral IL-23 peptide for immunology. Management is progressing a $55 billion US manufacturing and R&D investment through 2029, with $12 billion already deployed. The planned separation of its DePuy Synthes Orthopaedics business targets mid-2027 completion.

Business Wire
Apr 7th, 2026
Johnson & Johnson launches VARIPULSE Pro in Europe with 5x faster ablation for atrial fibrillation treatment

Johnson & Johnson has launched VARIPULSE Pro in Europe following CE Mark approval, advancing its pulsed field ablation portfolio for treating atrial fibrillation. The system features a new pulse sequence that operates five times faster than its predecessor whilst maintaining equivalent lesion quality. VARIPULSE Pro integrates with the CARTO 3 mapping system and offers a lower temperature profile whilst preserving the platform's established safety and effectiveness profiles. The company is conducting the VARIPURE multicentre study to generate clinical evidence during the commercial launch phase. The technology addresses atrial fibrillation, the most common cardiac arrhythmia affecting over 50 million people worldwide. Johnson & Johnson will showcase VARIPULSE Pro at the European Heart Rhythm Association annual meeting, with 12-month interim study results to be presented. The device is not currently approved in the United States.

Yahoo Finance
Apr 3rd, 2026
J&J's dividend stays resilient despite market sell-offs and healthcare challenges

Johnson & Johnson has raised $120 million in a Series C round led by Ribbit Capital, valuing the company at $1.45 billion. Sequoia and Kleiner Perkins participated, with Emerson Collective joining as a new backer. The pre-revenue company is developing "Mathematical Superintelligence", an AI system focused on advanced reasoning that claims to eliminate hallucinations by requiring outputs in Lean4 programming language. Its flagship model, Aristotle, achieved top-level performance at the International Mathematical Olympiad in July. Founded in 2023, Harmonic has raised $295 million across three funding rounds in 14 months. The company currently offers Aristotle via a free API and plans to commercialise in safety-critical industries like aerospace and finance.

Yahoo Finance
Apr 1st, 2026
J&J takes over NBTXR3 Phase III as Nanobiotix shifts to Curadigm, secures runway into early 2028

Nanobiotix has transferred full operational and financial responsibility for its NBTXR3 radioenhancer programme to Johnson & Johnson, with Phase III head-and-neck results expected in H1 2027 and Phase II lung cancer data anticipated in early 2027. The company is pivoting towards its Curadigm nanoprimer platform, filing four patents, starting GMP manufacturing and signing over 20 material transfer agreements with partners. Additional Curadigm data is expected before summer's end. An amended Janssen licence removing most Phase III funding obligations, combined with a royalty financing of up to $71 million, extends Nanobiotix's cash runway into early 2028. The company reported EUR 32.6 million revenue in 2025, reduced R&D spending to EUR 23.1 million, and EUR 52.8 million cash at year-end.

INACTIVE